News Headlines

  1. VivaMed BioPharma Partners With Syngene International To Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure 2/19/2026

    VivaMed BioPharma (VivaMed), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to discover and advance repurposed and improved therapeutic assets, today announced a strategic partnership with Syngene International, a leading global contract research, development and manufacturing organization.

  2. IBA And Shreeji Sign Multi Site Agreement For Four Cyclotrons To Expand PET Radiopharmaceutical Manufacturing Across India 2/19/2026

    IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-energy Cyclone® KIUBE 300 cyclotrons.

  3. Bavarian Nordic Receives USD 22.5 Million Contract For Its Mpox And Smallpox Vaccine From The Government Of Canada 2/18/2026

    Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine, MVA-BN®.

  4. Johnson & Johnson Expands U.S. Footprint With More Than $1B Investment In Next Generation Cell Therapy Manufacturing Facility In Pennsylvania 2/18/2026

    Johnson & Johnson (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1B investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.

  5. Cellares And University Of Wisconsin School Of Medicine And Public Health Expand Partnership To Clinical Manufacturing Of CRISPR-Edited CAR-T For Solid Tumors 2/18/2026

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and the University of Wisconsin (UW) School of Medicine and Public Health today announced an expansion of their partnership to support clinical production and regulatory advancement of the university’s CRISPR-edited GD2 CAR-T investigational therapy for pediatric and adult solid tumors.

  6. Unnatural Products Announces Licensing Agreement With Novartis To Develop Macrocyclic Peptide Therapeutics 2/18/2026

    Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced a research collaboration and licensing agreement with Novartis on an undisclosed program.

  7. Manus Expands HHS ASPR Partnership With $15M Award 2/18/2026

    In a move to strengthen America’s health security, Manus, the proven bioalternatives scale-up platform, today announced an expanded partnership with the U.S. Department of Health and Human Services’ (HHS) Center for Industrial Base Management and Supply Chain (IBMSC), which is part of the Administration for Strategic Preparedness and Response (ASPR).

  8. Catalent And S.Biomedics Announce Partnership To Develop And Manufacture TED A9 2/18/2026

    Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease.

  9. DFE Pharma Launches New CM Platform – With Gericke Technology 2/17/2026

    DFE Pharma, a global leader in pharmaceutical excipients, announced the launch of its Continuous Manufacturing (CM) platform, designed to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes.

  10. Scinai Announces Completion Of Acquisition Of Recipharm Israel Ltd. And Strategic Commercial Collaboration With Recipharm 2/17/2026

    Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm.